Navigation Links
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2011
Date:8/25/2011

NEW YORK, Aug. 25, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2011

http://www.reportlinker.com/p0293171/Partnerships-Licensing-Investments-and-MA-Deals-and-Trends-in-Pharmaceuticals---Q2-2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Healthcare

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2011

Summary

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2011" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&As, equity/debt offerings, private equity and venture financing transactions recorded in the pharmaceutical and healthcare industry in Q2 2011. The report presents detailed comparative data on the number of deals and their value in the last five quarters, categorized into deal types, segments, and geographies. The report also provides information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.

- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

- Analysis of partnership and licensing deals based on clinical stage of development of products.

- Summary of the pharmaceutical deals globally in the last five quarters.

- Information on the top deals happened in the pharmaceutical industry.

- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.

- Find out the major deal performing segments for investments in your industry.

- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

- Identify companies that are aggressively looking to raise capital in the market

- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

- Identify growth segments and opportunities in each region within the industry.

- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

1 Table of contents

1 Table of contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Pharmaceutical & Healthcare, Global, Deal Summary, Q2 2011 9

2.1 Pharmaceutical & Healthcare, Global, Deals Analysis, Q2 2011 9

2.2 Pharmaceutical & Healthcare, Global, by Type, Number of Deals and Deal Values, Q2 2011 11

2.3 Pharmaceutical & Healthcare, Global, Top Deals, Q2 2011 12

2.3.1 Takeda Pharmaceutical To Acquire Nycomed International 12

2.3.2 Teva Pharmaceutical To Acquire Cephalon 12

2.3.3 Johnson & Johnson Completes Public Offering Of Senior Unsecured Notes For $4.4 Billion 12

2.3.4 Ashland To Acquire International Specialty Products 13

2.3.5 Amgen Completes Public Offering Of Senior Unsecured Notes For $3 Billion 13

3 Pharmaceutical & Healthcare, Global, Deals Summary, by Type 14

3.1 Pharmaceutical & Healthcare, Global, M&A, Q2 2011 14

3.1.1 Top M&A Deals in Q2 2011 15

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q2 2010 - Q2 2011 16

3.2 Pharmaceutical & Healthcare, Global, Equity Offering Deals, Q2 2011 17

3.2.1 Top Initial Public Offerings in Q2 2011 18

3.2.2 Top Secondary Offerings in Q2 2011 18

3.2.3 Top PIPE Deals in Q2 2011 18

3.2.4 Pharmaceutical & Healthcare, Global, Top IPOs Share Performance, Q2 2010–Q2 2011 19

3.2.5 Pharmaceutical & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q2 2010 – Q2 2011 20

3.3 Pharmaceutical & Healthcare, Global, Debt Offering Deals, Q2 2011 21

3.3.1 Top Public Debt Offerings in Q2 2011 22

3.3.2 Top Private Debt Placements in Q2 2011 22

3.3.3 Pharmaceutical & Healthcare, Global, Debt Offering Deals, by Therapy Area, Q2 2010 - Q2 2011 23

3.4 Pharmaceutical & Healthcare, Global, Venture Capital Deals, Q2 2011 24

3.4.1 Top Venture Financing Deals in Q2 2011 25

3.4.2 Pharmaceutical & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q2 2011 26

3.4.3 Pharmaceutical & Healthcare, Global, Venture Capital, by Therapy Area, Q2 2010 - Q2 2011 27

3.4.4 Pharmaceutical & Healthcare, Global, Top Venture Financing Firms, Last Four Quarters 28

3.4.5 Pharmaceutical & Healthcare, Global, Top VC Backed Companies, Last One Year 29

3.5 Pharmaceutical & Healthcare, Global, Private Equity Deals, Q2 2011 30

3.5.1 Top Private Equity Deals in Q2 2011 31

3.5.2 Pharmaceutical & Healthcare, Global, Private Equity Deals, by Therapy Area, Q2 2010 - Q2 2011 32

4 Pharmaceutical & Healthcare, Global, Partnership Deals, Q2 2011 33

4.1 Pharmaceutical & Healthcare, Global, Partnership Deals, Q2 2011 33

4.2 Pharmaceutical & Healthcare, Global, Partnership Deals, by Therapy Area, Q2 2010 - Q2 2011 34

4.3 Pharmaceutical & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2011 35

4.3.1 Pharmaceutical & Healthcare, Global, Top Partnership Deals, by Deal Values, Q2 2011 36

4.3.2 Pharmaceutical & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q2 2011 36

4.3.3 Pharmaceutical & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q2 2011 37

4.4 Pharmaceutical & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2010 - Q2 2011 38

4.5 Pharmaceutical & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 39

4.6 Pharmaceutical & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2010 - Q2 2011 40

5 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q2 2011 41

5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q2 2011 41

5.2 Pharmaceutical & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2010 - Q2 2011 42

5.2.1 Pharmaceutical & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q2 2011 43

5.2.2 Pharmaceutical & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q2 2011 43

5.2.3 Pharmaceutical & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q2 2011 44

5.2.4 Pharmaceutical & Healthcare, Global, Licensing Agreements with Equity Investment, Q2 2010 – Q2 2011 44

5.3 Pharmaceutical & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q2 2010 - Q2 2011 45

5.4 Pharmaceutical & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q2 2010 - Q2 2011 46

5.5 Pharmaceutical & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q2 2010 - Q2 2011 47

5.6 Pharmaceutical & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q2 2010 - Q2 2011 48

6 Pharmaceutical & Healthcare, Global, M&A Financial Analysis 49

6.1 Pharmaceutical & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q2 2010 - Q2 2011 49

6.2 Pharmaceutical & Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q2 2010 - Q2 2011 50

6.3 Pharmaceutical & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q2 2010 - Q2 2011 51

6.4 Pharmaceutical & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q2 2010 - Q2 2011 52

6.5 Pharmaceutical & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q2 2010 - Q2 2011 53

6.6 Pharmaceutical & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q2 2010 - Q2 2011 54

6.7 Pharmaceutical & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q2 2010 - Q2 2011 55

7 Pharmaceutical & Healthcare, Global, Deal Summary by Therapy Area 56

7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q2 2011 56

7.1.1 Oncology – Deals of the Quarter 57

7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q2 2011 58

7.2.1 Central Nervous System – Deals of the Quarter 59

7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q2 2011 60

7.3.1 Infectious Disease – Deals of the Quarter 61

7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q2 2011 62

7.4.1 Immunology – Deals of the Quarter 63

7.5 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q2 2011 64

7.5.1 Cardiovascular – Deals of the Quarter 65

7.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q2 2011 66

7.6.1 Metabolic Disorders – Deals of the Quarter 67

7.7 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q2 2011 68

7.7.1 Respiratory – Deals of the Quarter 69

7.8 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q2 2011 70

7.8.1 Gastrointestinal – Deals of the Quarter 71

7.9 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q2 2011 72

7.9.1 Dermatology – Deals of the Quarter 73

7.10 Pharmaceuticals & Healthcare, Global, Musculoskeletal Deals, Q2 2011 74

7.10.1 Musculoskeletal – Deals of the Quarter 75

8 Deal Summary by Geography 76

8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q2 2011 76

8.1.1 North America – Deals of the Quarter 77

8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q2 2011 78

8.2.1 Europe – Deals of the Quarter 79

8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q2 2011 80

8.3.1 Asia-Pacific – Deals of the Quarter 81

8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q2 2011 82

8.4.1 Rest of the World – Deals of the Quarter 83

9 Pharmaceuticals & Healthcare, Global, Top Advisors 84

9.1 Pharmaceutical & Healthcare, Global Top Financial Advisors, M&A, Last One Year 84

9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Last One Year 85

10 Further Information 86

10.1 Methodology 86

10.2 About GlobalData 86

10.3 Contact Us 87

10.4 Disclosure information 87

10.5 Disclaimer 87

List of Tables

Table 1: Pharmaceutical & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q2 2010 - Q2 2011 10

Table 2: Pharmaceutical & Healthcare, Global, Number Of Deals and Deal Values (%), Q2 2011 11

Table 3: Pharmaceutical & Healthcare, Global, Top Deals, Q2 2011 12

Table 4: Pharmaceutical & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2010 – Q2 2011 14

Table 5: Pharmaceutical & Healthcare, Global, Top M&A Deals, Q2 2011 15

Table 6: Pharmaceutical & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q2 2010 - Q2 2011 16

Table 7: Pharmaceutical & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2010 - Q2 2011 17

Table 8: Pharmaceutical & Healthcare, Global, Top Initial Public Offering Deals, Q2 2011 18

Table 9: Pharmaceutical & Healthcare, Global, Top Secondary Offering Deals, Q2 2011 18

Table 10: Pharmaceutical & Healthcare, Global, Top PIPE Deals, Q2 2011 18

Table 11: Pharmaceutical & Healthcare, Global, Top IPOs Share Performance, Q2 2010–Q2 2011 19

Table 12: Pharmaceutical & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2010 - Q2 2011 20

Table 13: Pharmaceutical & Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 21

Table 14: Pharmaceutical & Healthcare, Global, Top Public Debt Offerings, Q2 2011 22

Table 15: Pharmaceutical & Healthcare, Global, Top Private Debt Placements, Q2 2011 22

Table 16: Pharmaceutical & Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 23

Table 17: Pharmaceutical & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 24

Table 18: Pharmaceutical & Healthcare, Global, Top Venture Capital Deals, Q2 2011 25

Table 19: Pharmaceutical & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q2 2011 26

Table 20: Pharmaceutical & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2010 - Q2 2011 27

Table 21: Pharmaceutical & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q3 2010 – Q2 2011 28

Table 22: Pharmaceutical & Healthcare, Global, Top VC Backed Companies, Q3 2010 – Q2 2011 29

Table 23: Pharmaceutical & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2010 – Q2 2011 30

Table 24: Pharmaceutical & Healthcare, Global, Top Private Equity Deals, Q2 2011 31

Table 25: Pharmaceutical & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2010 - Q2 2011 32

Table 26: Pharmaceutical & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 33

Table 27: Pharmaceutical & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 34

Table 28: Pharmaceutical & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2010 - Q2 2011 35

Table 29: Pharmaceutical & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2011 36

Table 30: Pharmaceutical & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q2 2011 36

Table 31: Pharmaceutical & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q2 2011 37

Table 32: Pharmaceutical & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q2 2010 - Q2 2011 38

Table 33: Pharmaceutical & Healthcare, Global, Partnership Deals, by Phase, Q2 2010 - Q2 2011 39

Table 34: Pharmaceutical & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q2 2010 - Q2 2011 40

Table 35: Pharmaceutical & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 41

Table 36: Pharmaceutical & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2010 - Q2 2011 42

Table 37: Pharmaceutical & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q2 2011 43

Table 38: Pharmaceutical & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q2 2011 43

Table 39: Pharmaceutical & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q2 2011 44

Table 40: Pharmaceutical & Healthcare, Global, Licensing Agreements with Equity Investment, Q2 2010 – Q2 2011 44

Table 41: Pharmaceutical & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 45

Table 42: Pharmaceutical & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q2 2010 - Q2 2011 46

Table 43: Pharmaceutical & Healthcare, Global, Partnership Deals, by Phase, Q2 2010 - Q2 2011 47

Table 44: Pharmaceutical & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q2 2010 - Q2 2011 48

Table 45: Pharmaceutical & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q2 2010 - Q2 2011 49

Table 46: Pharmaceutical & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q2 2010 - Q2 2011 50

Table 47: Pharmaceutical & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q2 2010 - Q2 2011 51

Table 48: Pharmaceutical & Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q2 2010 - Q2 2011 52

Table 49: Pharmaceutical & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q3 2009 - Q2 2011 53

Table 50: Pharmaceutical & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q2 2010 - Q2 2011 54

Table 51: Pharmaceutical & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q2 2010 - Q2 2011 55

Table 52: Pharmaceutical & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 57

Table 53: Pharmaceutical & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 59

Table 54: Pharmaceutical & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 61

Table 55: Pharmaceutical & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 63

Table 56: Pharmaceutical & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 65

Table 57: Pharmaceutical & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 67

Table 58: Pharmaceutical & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 69

Table 59: Pharmaceutical & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 70

Table 60: Pharmaceutical & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 73

Table 61: Pharmaceutical & Healthcare, Global, Musculoskeletal, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 75

Table 62: Pharmaceutical & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 77

Table 63: Pharmaceutical & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 79

Table 64: Pharmaceutical & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 81

Table 65: Pharmaceutical & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 83

Table 66: Pharmaceutical & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q3 2010 - Q2 2011 84

Table 67: Pharmaceutical & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q3 2010 - Q2 2011 85

1.2 List of Figures

Figure 1: Pharmaceutical & Healthcare, Global, Number of Deals and Deal Values (US$m), Q2 2010 - Q2 2011 9

Figure 2: Pharmaceutical & Healthcare, Global, Number Of Deals (%) and Deal Values (%), Q2 2011 11

Figure 3: Pharmaceutical & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q2 2010 - Q2 2011 14

Figure 4: Pharmaceutical & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q2 2010 – Q2 2011 16

Figure 5: Pharmaceutical & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 17

Figure 6: Pharmaceutical & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q2 2010 – Q2 2011 20

Figure 7: Pharmaceutical & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$m), Q2 2010 - Q2 2011 21

Figure 8: Pharmaceutical & Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), , Q2 2010 - Q2 2011 23

Figure 9: Pharmaceutical & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 24

Figure 10: Pharmaceutical & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%) and Deal Values (%), Q2 2011 26

Figure 11: Pharmaceutical & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q2 2010 - Q2 2011 27

Figure 12: Pharmaceutical & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q3 2010 – Q2 2011 28

Figure 13: Pharmaceutical & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q2 2010 – Q2 2011 30

Figure 14: Pharmaceutical & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q2 2010 - Q2 2011 32

Figure 15: Pharmaceutical & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 33

Figure 16: Pharmaceutical & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 34

Figure 17: Pharmaceutical & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q2 2010 - Q2 2011 35

Figure 18: Pharmaceutical & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q2 2010 - Q2 2011 38

Figure 19: Pharmaceutical & Healthcare, Global, Partnership Deals, by Phase, Q2 2010 - Q2 2011 39

Figure 20: Pharmaceutical & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q2 2010 - Q2 2011 40

Figure 21: Pharmaceutical & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 41

Figure 22: Pharmaceutical & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q2 2010 - Q2 2011 42

Figure 23: Pharmaceutical & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 45

Figure 24: Pharmaceutical & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2010 - Q2 2011 46

Figure 25: Pharmaceutical & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 47

Figure 26: Pharmaceutical & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2010 - Q2 2011 48

Figure 27: Pharmaceutical & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q2 2010 - Q2 2011 49

Figure 28: Pharmaceutical & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q2 2010 - Q2 2011 50

Figure 29: Pharmaceutical & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q2 2010 - Q2 2011 51

Figure 30: Pharmaceutical & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q2 2010 - Q2 2011 52

Figure 31: Pharmaceutical & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share), Q2 2010 - Q2 2011 53

Figure 32: Pharmaceutical & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q2 2010 - Q2 2011 54

Figure 33: Pharmaceutical & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q2 2010 - Q2 2011 55

Figure 34: Pharmaceutical & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 56

Figure 35: Pharmaceutical & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 58

Figure 36: Pharmaceutical & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 60

Figure 37: Pharmaceutical & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 62

Figure 38: Pharmaceutical & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 64

Figure 39: Pharmaceutical & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 66

Figure 40: Pharmaceutical & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 68

Figure 41: Pharmaceutical & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 70

Figure 42: Pharmaceutical & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 72

Figure 43: Pharmaceutical & Healthcare, Global, Musculoskeletal, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 74

Figure 44: Pharmaceutical & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 76

Figure 45: Pharmaceutical & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 78

Figure 46: Pharmaceutical & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 80

Figure 47: Pharmaceutical & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q2 2010 - Q2 2011 82

Figure 48: Pharmaceutical & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q3 2010 - Q2 2011 84

Figure 49: Pharmaceutical & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q3 2010 - Q2 2011 85

Companies Mentioned

To order this report:

Healthcare Industry: Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2011

Healthcare Business News

More  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Kimberly-Clark Health Care Announces Strategic Green Partnerships, Commitment to Reducing Medical Waste
2. Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco
3. MGT Capital Investments, Inc. Provides Update on Recent Developments
4. Visionary Pharmaceuticals, Inc., Announces Initial Seed Round Investments and the Launch of TH17 Autoimmune Disease Research Activities
5. Apax Partners, CPPIB and PSP Investments to Acquire Kinetic Concepts, Inc. for $68.50 per Share
6. Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years
7. MGT Capital Investments Receives NYSE Amex Listing Deficiency Notification
8. Michigan Pre-Seed Capital Fund Reports Investments Totaling $2.5 Million in 2010
9. PharmaNets Technology Investments Translate to Enhanced Client Service in Its Phase I Clinics
10. Pittsburgh Life Sciences Greenhouse and Innovation Works Announce Investments in Ib2C™
11. Governor Rendell: New State Investments Bear Fruit in Adams County; Help Pharmaceutical Company Expand in Philadelphia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  Syneron Medical Ltd. ... device company, announced today that William Griffing ... America, is scheduled to participate in the Leerink ... on February 11, 2016 in New ... institutional investors to meet with the Mr. Griffing ...
(Date:2/5/2016)... Ala. , Feb. 5, 2016  Patients in ... high intensity focused ultrasound (HIFU) therapy no longer have to ... to announce its partnership with Urology Centers of Alabama ... the newly FDA-cleared procedure for qualifying patients. ... their expertise in the treatment of prostate cancer using many ...
(Date:2/5/2016)... Feb. 5, 2016 Aethlon Medical, Inc. (Nasdaq: ... and CEO, will be presenting at Source Capital Group,s 2016 ... NY at 2:15 p.m. ET on Wednesday, February ... Panel discussion taking place at 3:15 p.m. ET. ... one hour after the conclusion of the live event. The ...
Breaking Medicine Technology:
(Date:2/7/2016)... ... February 07, 2016 , ... Women’s Excellence now ... the most minimally invasive approaches. , Women who have had multiple vaginal births ... factors include surgery to the pelvic floor, connective tissue disorders, and obesity. Women ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... empowers employers and organizations with the tools and information to lower the costs, ... to cut the cost of providing employee healthcare benefits by as much as ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... , MEDIA ADVISORY: 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & ... nurses in the world with an estimated 5000 perioperative nurses in attendance ...
(Date:2/6/2016)... ... 06, 2016 , ... With the FCPX LUT: Summer pack from ... footage. A LUT is a Lookup Table that contains a mathematical formula for modifying ... the table. By manipulating each pixel, LUT's can change each color range differently, it ...
(Date:2/6/2016)... ... February 06, 2016 , ... Research has shown ... to reduce the frequency and level of relapse. , At the ... and Purpose,” will explore the critical tasks of the recovery phase and beyond ...
Breaking Medicine News(10 mins):